The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Acadia Pharmaceuticals (Nasdaq: ACAD) is a leading pharmaceutical company with a focus on bringing life-changing therapies to patients suffering from CNS diseases.
A workshop held at the International Association for the Study of Pain (IASP) World Congress has revealed significant discrepancies in clinical practice guidelines (CPGs) across countries for opioid use in chronic pain management. 29 August 2024
Flagship Pioneering yesterday demonstrated further acceleration in its strategic partnership with Pfizer, announcing two research programs with Flagship-founded Quotient Therapeutics. 29 August 2024
Japanese drugmaker Chugai Pharmaceutical says it will transfer the business of the secondary hyperparathyroidism drug Oxarol for Injection (maxacalcitol) to LTL Pharma in Japan. 29 August 2024
Drug development consultancy Certara has published a report on the Inflation Reduction Act’s (IRA) impact on oncology biosimilar uptake. 29 August 2024
German pharma major Bayer today announced it has entered into a collaboration and license agreement with US biotech start-up NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology. 28 August 2024
Chinese biotech DualityBio has shown that it means business in a filing to the Hong Kong stock exchange that reveals its plans for an initial public offering (IPO). 28 August 2024
Novartis today announced positive top-line results from twice-yearly Leqvio (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. 28 August 2024
Japanese pharma major Astellas Pharma today revealed that the European Commission has granted Marketing Authorization for Padcev (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with Keytruda (pembrolizumab). 28 August 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Bristol Myers Squibb has scored a major legal victory as a judge in New York dismissed a $6.4 billion lawsuit related to its acquisition of cancer company Celgene. 1 October 2024